Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06150781 · ClinicalTrials.gov registry record
Aimovig Pregnancy Exposure Registry
A clinical trial of Migraine, sponsored by Amgen.
- Recruiting
- Registry status
- 2,842
- Enrollment target
- 1
- Study location
NCT06150781 is a study of Migraine that is actively recruiting participants, run by Amgen. The registered enrollment target is 2,842 participants, above the 330-participant average among 102 other Migraine trials with a reported enrollment target (761% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06150781, a study of Migraine, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- 2,842 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
Conditions Studied
Interventions
- DRUG erenumab-aooe
Study Locations (1)
North Carolina
- IQVIA Virtual Site - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,842 participants |
| Start Date | 2021-01-27 |
| Est. Completion | 2027-10-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06150781
The ClinicalTrials.gov registry entry for NCT06150781 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,842 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 330-participant average among 102 other Migraine trials with a reported enrollment target (761% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which erenumab-aooe is the first listed.
NCT06150781 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06150781 about?
NCT06150781 is a clinical study titled "Aimovig Pregnancy Exposure Registry". The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
What is the current status of trial NCT06150781?
This trial is currently recruiting. The enrollment target is 2,842 participants. The study started on 2021-01-27. Estimated completion is 2027-10-28.
What conditions does trial NCT06150781 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06150781?
The interventions under investigation include: erenumab-aooe (DRUG).
Who is sponsoring clinical trial NCT06150781?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06150781 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.